Document Detail


A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.
MedLine Citation:
PMID:  8778585     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Thrombin has a pivotal role in the pathogenesis of acute coronary thrombosis. We compared the clinical efficacy of a potent, direct thrombin inhibitor, recombinant hirudin, with that of heparin (an indirect antithrombin agent) in patients with unstable angina or acute myocardial infarction. METHODS: At 373 hospitals in 13 countries, 12,142 patients with acute coronary syndromes were randomly assigned to 72 hours of therapy with either intravenous heparin or hirudin. Patients were stratified according to the presence of ST-segment elevation on the base-line electrocardiogram (4131 patients) or its absence (8011 patients), with the latter characteristic considered to indicate unstable angina or non-Q-wave myocardial infarction. RESULTS: At 24 hours, the risk of death or myocardial infarction was significantly lower in the group assigned to hirudin therapy than in the group assigned to heparin (1.3 percent vs. 2.1 percent, P = 0.001). The primary end point of death or nonfatal myocardial infarction or reinfarction at 30 days was reached in 9.8 percent of the heparin group as compared with 8.9 percent of the hirudin group (odds ratio for the risk of the end point in hirudin group,0.89; 95 percent confidence interval, 0.79 to 1.00; P = 0.06). The predominant effect of hirudin was on myocardial infarction or reinfarction and was not influenced by ST-segment status. There were no significant differences in the incidence of serious or life-threatening bleeding complications, but hirudin therapy was associated with a higher incidence of moderate bleeding (8.8 percent vs. 7.7 percent, P = 0.03). CONCLUSIONS: For acute coronary syndromes, recombinant hirudin provided a small advantage, as compared with heparin, principally related to a reduction in the risk of nonfatal myocardial infarction. The relative therapeutic effect was more pronounced early (at 24 hours) but dissipated over time. The small benefit was consistent across the spectrum of acute coronary syndromes and was not associated with a greater risk of major bleeding complications.
Authors:
-
Related Documents :
1834805 - Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for syn...
18382265 - Clopidogrel use in coronary heart disease and percutaneous coronary intervention.
12193965 - Platelet glycoprotein iib/iiia receptor blockade with integrilin (eptifibatide) for ear...
19101225 - Temporal course of pregnancy-associated plasma protein-a in angioplasty-treated st-elev...
8407005 - Prognosis after a first q-wave myocardial infarction in ethnic chinese people: a prospe...
20096285 - Electrophysiological remodeling in heart failure.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The New England journal of medicine     Volume:  335     ISSN:  0028-4793     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  1996 Sep 
Date Detail:
Created Date:  1996-09-19     Completed Date:  1996-09-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  775-82     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angina, Unstable / drug therapy*,  mortality
Antithrombins / therapeutic use*
Double-Blind Method
Female
Fibrinolytic Agents / therapeutic use*
Heparin / therapeutic use*
Hirudin Therapy*
Humans
Incidence
Male
Middle Aged
Myocardial Infarction / drug therapy*,  epidemiology,  mortality
Partial Thromboplastin Time
Recombinant Proteins / therapeutic use
Recurrence
Survival Analysis
Chemical
Reg. No./Substance:
0/Antithrombins; 0/Fibrinolytic Agents; 0/Recombinant Proteins; 9005-49-6/Heparin
Comments/Corrections
Comment In:
N Engl J Med. 1997 Mar 6;336(10):730; author reply 730-1   [PMID:  9045050 ]
ACP J Club. 1997 Mar-Apr;126(2):33

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syn...
Next Document:  Meningococcal disease in Los Angeles County, California, and among men in the county jails.